Search Results - listed+lpm+vathyam+as+of+4%2f15%2f2015

3 Results

Sort By:

Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers

The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer...

Published: 7/25/2024 | Inventor(s): Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Lesley Mathews, Heide Ford, Melanie Blevins, Rebecca Mull, Rui Zhao

Keywords(s): cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology

Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells

Monoclonal antibodies (mAbs) have become a mainstay of therapy for many cancers. However, antibody therapy is not completely effective in some applications due to loss of the target surface antigen on cancer cells. Such mAb-induced “escape variants” are no longer sensitive to the therapeutic mAb therapy. It was observed that the escape variants carried...

Published: 7/25/2024 | Inventor(s): Martin Skarzynski, Margaret Lindorfer, Ronald Taylor, Christoph Rader, Berengere Vire, Erika Gaglione, Haiyong Peng, Sivasubramanian Baskar, Adrian Wiestner

Keywords(s): 2JXXXX, 4GXXXX, 5OXXXX, ANTIBODY, C3, C3d, CANCER, CB1XXX, Cell, Cells, Complement, Deposited, Listed LPM Vathyam as of 4/15/2015, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Potentiating, Pre LPM working set 20150418, Protein, Surface, Targeting, THERAPY, THEROF, VCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7

A highly efficient method to genetically modify natural killer (NK) cells to induce expression of high affinity CD16 (HA-CD16) through mRNA electroporation, to potentiate NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). ADCC is mediated by CD16+ NK cells following adoptive NK cell transfer, but most humans express CD16 which has a relatively...

Published: 7/25/2024 | Inventor(s): Mattias Carlsten, Richard Childs

Keywords(s): ADCC, antibodies, ANTIBODY, CBXXXX, CD16, ex vivo, Listed LPM Vathyam as of 4/15/2015, monoclonal, NK, NK Cells, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TRANSFECTION, TUMORS, VCXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology